MedTrace Logo

Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects

NCT06609525 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2024-09-24

No results posted yet for this study

Summary

This is a prospective randomized study compared with active control arm.

Conditions

  • Pupillary Dilation Effect During Cycloplegic Refraction

Interventions

DRUG

CTO0303-A

eye drop, 1 drop 3 times (every 5 minutes) a day

DRUG

CTO0303-B

eye drop, 1 drop 3 times (every 5 minutes) a day

DRUG

CTO0303-C

eye drop, 1 drop 3 times (every 5 minutes) a day

Sponsors & Collaborators

  • Taejoon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-09
Primary Completion
2024-12-31
Completion
2025-03-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06609525 on ClinicalTrials.gov